Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report.
The addition of 5 days of rifampin therapy to a 10- or 14-day course of penicillin or erythromycin therapy has been shown to reduce greatly the rate of chronic streptococcal carriage. The empiric use of rifampin in combination with penicillin or erythromycin in nine of nine patients with streptococcal-associated psoriasis appeared to coincide with a marked improvement in their skin.
D000328:Adult; D002353:Carrier State / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010404:Penicillin V / Q000627:therapeutic use*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use*; D012874:Skin Diseases, Infectious / Q000150:complications / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000150:complications / Q000188:drug therapy*
D004917:Erythromycin; D012293:Rifampin; D010404:Penicillin V